Skip to main content
. 2008 Nov 10;26(35):5802–5812. doi: 10.1200/JCO.2008.16.4368

Table 1.

Characteristics of Included Studies

Trial Accrual Period Stage Affected Para-Aortic Nodes Excluded? Comparison Concomitant CT (dose in mg/m2) CT Schedule
RT (Gy) BRT(Gy to point A) RT Duration (days) No. of Patients
No. of Cycles Frequency (weeks)
Main analysis
    *Thomas (a)24 1987-1995 Ib (>5 cm) to IVa No RT v CTRT IV FU 32 mg/m2 2 3 50 40 < 56 116
    *Thomas (b)24 1987-1995 Ib (>5 cm) to IVa No Hyperfractionated RT v hyperfractionated CTRT IV FU 32 mg/m2 2 3 50 40 < 56 118
    *†Lorvidhaya (a)25 1987-1994 IIb, IIIb to IVa No RT v CTRT MMC 10 mg/m2 2 4 50 28 49-56 475
FU (oral) 4,200 mg
    *†Lorvidhaya (b)25 1987-1994 IIb, IIIb to IVa No RT + Adj CT v CTRT + Adj CT MMC 10 mg/m2, FU (oral) 4,200 mg 2 4 50 28 49-56 451
3 4
Adj FU 5,600 mg (oral)
    Onishi44 1988-1998 IIb to IV No RT v CTRT CDDP1: 100 mg/m2 2 2-3 50 24 45-55 49
CDDP2: 50 mg/m2 3 1
CBDCA: 100 mg/m2 6 1
    Roberts49 1991-2001 Ib2, II to IVa No RT v CTRT MMC 30 mg/m2 2 6 IB2-IIB: 40‡ 45-50 Not specified 248
III-IVA: 46‡ 40-45
    Peters8,46 SWOG8797 1991-1996 Ia2 to IIa No S + RT v S + CTRT + CT CDDP 70 mg/m2 4 3 49.3 None 42 268
FU 4,000 mg/m2
    Pearcey43 1991-1996 Ib-IIb (> 4 cm) III to IVa No RT v CTRT CDDP 40 mg/m2 5 1 45 24-35 46-56 259
    Keys6 GOG0123 1992-1997 Ib (bulky) Yes S + RT v S + CTRT CDDP 40 mg/m2 6 1 45 30 < 70 374
    *Chen (a)23 1993-1994 IIb to III No RT v CTRT CDDP 60 mg/m2 2 3 40 50 49 60
FU 1,500 mg/m2
VCR 2 mg/m2
    *Chen (b)23 1993-1994 IIb to III No RT + hyperthermia v CTRT + hyperthermia CDDP 60 mg/m2 2 3 40 50 49 60
FU 1,500 mg/m2
VCR 2 mg/m2
    Pras 1995-1999 Ib to IIa >4 cm Yes RT v CTRT CDBCA 300 mg/m2 3 4 45 35 > 56 54
IIb to IVa FU 2,400 mg/m2
    Leborgne 1995-2004 Ib2 to IVb No RT v CTRT CDDP 80 mg/m2 2 4 40 42 40 340
FU 2,400 mg/m2
    Garipagaoglu48 1996-1997 IIb, IIIb No RT v CTRT CDDP 120 mg/m2 2 3 46-50 20 61-62 44
    Kantardzic45 1996-1999 IIb to III No RT v CTRT + CT CDDP 40 mg/m2 6 3 46 25-30 56-60 80
BLM 15 mg/m2 6 3
    *Lanciano (a)26 GOG0165 1997-1998 IIb, IIIb, IVa Yes RT v CTRT CDDP 40 mg/m2 6 1 45 30 (HDR) or 40 (LDR) < 56 50
    *Lanciano (b)26 GOG0165 1997-1998 IIb, IIIb, IVa Yes RT v CTRT FU 1,125 mg/m2 6 1 45 30 (HDR) or 40 (LDR) < 56 51
    Lal50 2000-2006 II to IV No RT v CTRT CDDP 35 mg/m2 5 1 50 18 63 180
    Cikaric47 2002-2003 IIb to IVa No RT v CTRT CDDP 40 mg/m2 5 1 46 35 45 200
Sensitivity analysis
    Whitney10 GOG0085 1986-1990 IIb to IVa Yes RT + HU v CTRT CDDP 50 mg/m2 2 4 40.8 or 51 or 61.2 40 < 70 388
FU 4,000 mg/m2 40
0
    §Morris7,17 RTOG9001 1990-1997 Ib to IIa (>4 cm or positive pelvic nodes) Yes RT v CTRT CDDP 75 mg/m2 3 3 45 40 < 56 403
FU 4,000 mg/m2
IIb to IVa
    *Rose (a)9 GOG0120 1992-1997 IIb to IVa Yes RT + HU v CTRT CDDP 40 mg/m2 6 1 40.8 or 51 or 61.2 40 70 384
40
0
    *Rose (b)9 GOG0120 1992-1997 IIb to IVa Yes RT + HU vCTRT + HU CDDP 50 mg/m2 2 4 40.8 or 51 or 61.2 40 70 383
FU 4,000 mg/m2 40
HU (oral) 2 g/m2 1 6 0

Abbreviations: CT, chemotherapy; RT, radiotherapy; BRT, brachytherapy; CTRT, chemoradiotherapy; IV, intravenous; FU, fluorouracil; MMC, mitomycin; Adj, adjuvant; CDDP, cisplatin; CDBCA, carboplatin; S, surgery; VCR, vincristine; BLM, bleomycin; HDR, high-dose rate; LDR, low-dose rate; HU, hydroxyurea; GOG, Gynecologic Oncology Group; RTOG, Radiation Therapy Oncology Group.

*

Three-arm and four-arm trials were analyzed as two separate trials.

†

After 673 patients were randomly assigned, FU was given 300 mg/day (oral) Monday through Friday for duration of external-beam radiotherapy.

‡

With or without 8- to 10-Gy parametrial boost.

§

Extended-field external-beam radiotherapy (to para-aortic nodes) given on the control arm.